JP2021524255A - 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 - Google Patents

単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 Download PDF

Info

Publication number
JP2021524255A
JP2021524255A JP2020565399A JP2020565399A JP2021524255A JP 2021524255 A JP2021524255 A JP 2021524255A JP 2020565399 A JP2020565399 A JP 2020565399A JP 2020565399 A JP2020565399 A JP 2020565399A JP 2021524255 A JP2021524255 A JP 2021524255A
Authority
JP
Japan
Prior art keywords
seq
tmeff2
antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020565399A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019224713A5 (https=
JP2021524255A5 (https=
Inventor
クーパー，フィリップ
アーンスト，ロビン
ガネサン，ラジクマール
ケイン，コリーン
ラッセル，マイケル
シンハ，サンジャヤ
ヴェンカタラマニ，サチャデヴィ
ウ，シェン−ジウン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2021524255A publication Critical patent/JP2021524255A/ja
Publication of JPWO2019224713A5 publication Critical patent/JPWO2019224713A5/ja
Publication of JP2021524255A5 publication Critical patent/JP2021524255A5/ja
Priority to JP2024076617A priority Critical patent/JP2024105476A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020565399A 2018-05-24 2019-05-21 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用 Pending JP2021524255A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076617A JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675957P 2018-05-24 2018-05-24
US62/675,957 2018-05-24
PCT/IB2019/054184 WO2019224713A2 (en) 2018-05-24 2019-05-21 Monospecific and multispecific anti-tmeff2 antibodies and there uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076617A Division JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Publications (3)

Publication Number Publication Date
JP2021524255A true JP2021524255A (ja) 2021-09-13
JPWO2019224713A5 JPWO2019224713A5 (https=) 2022-05-25
JP2021524255A5 JP2021524255A5 (https=) 2022-05-25

Family

ID=67211771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565399A Pending JP2021524255A (ja) 2018-05-24 2019-05-21 単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
JP2024076617A Pending JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076617A Pending JP2024105476A (ja) 2018-05-24 2024-05-09 単一特異性及び二重特異性抗体抗－ｔｍｅｆｆ２抗体並びにそれらの使用

Country Status (25)

Country Link
US (1) US11866499B2 (https=)
EP (1) EP3802607A2 (https=)
JP (2) JP2021524255A (https=)
KR (1) KR20210011999A (https=)
CN (1) CN112703203B (https=)
AR (1) AR115419A1 (https=)
AU (1) AU2019274652B2 (https=)
BR (1) BR112020023416A2 (https=)
CA (1) CA3101304A1 (https=)
CL (1) CL2020003032A1 (https=)
CO (1) CO2020014515A2 (https=)
CR (1) CR20200564A (https=)
EA (1) EA202092849A1 (https=)
EC (1) ECSP20075234A (https=)
IL (1) IL278862A (https=)
JO (1) JOP20200295A1 (https=)
MA (1) MA52772A (https=)
MX (1) MX2020012589A (https=)
NI (1) NI202000087A (https=)
PE (1) PE20210634A1 (https=)
PH (1) PH12020551948A1 (https=)
SG (1) SG11202011268VA (https=)
TW (1) TWI865451B (https=)
UY (1) UY38243A (https=)
WO (1) WO2019224713A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
CA3164972A1 (en) * 2019-12-18 2021-06-24 Janssen Biotech, Inc. Materials and methods for in vivo biological targeting
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
US20230374140A1 (en) * 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
CA3266816A1 (en) * 2022-09-09 2024-03-14 Janssen Biotech, Inc. CANCER TREATMENT METHOD WITH AN ANTI-TMEFF2XCD3 BISPECIFIC ANTIBODY

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502092A (ja) * 2002-03-08 2006-01-19 プロテイン デザイン ラブス インコーポレイティド ガン抗原ｔｍｅｆｆ２に対する抗体及びそれらの使用
JP2011504460A (ja) * 2007-10-19 2011-02-10 ジェネンテック， インコーポレイテッド システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2016179003A1 (en) * 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016204966A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
HRP20231356T1 (hr) 2012-12-14 2024-02-16 Omniab, Inc. Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
KR102216003B1 (ko) 2013-03-15 2021-02-16 얀센 바이오테크 인코포레이티드 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JO3568B1 (ar) 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
EP3370768B9 (en) * 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502092A (ja) * 2002-03-08 2006-01-19 プロテイン デザイン ラブス インコーポレイティド ガン抗原ｔｍｅｆｆ２に対する抗体及びそれらの使用
JP2011504460A (ja) * 2007-10-19 2011-02-10 ジェネンテック， インコーポレイテッド システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2016179003A1 (en) * 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016204966A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE, vol. 321, JPN6023024559, 2008, pages 974 - 977, ISSN: 0005086975 *

Also Published As

Publication number Publication date
KR20210011999A (ko) 2021-02-02
US11866499B2 (en) 2024-01-09
CR20200564A (es) 2021-06-21
JOP20200295A1 (ar) 2020-11-22
WO2019224713A2 (en) 2019-11-28
EP3802607A2 (en) 2021-04-14
US20190359711A1 (en) 2019-11-28
AR115419A1 (es) 2021-01-13
BR112020023416A2 (pt) 2021-02-17
UY38243A (es) 2019-11-29
JP2024105476A (ja) 2024-08-06
TW202003584A (zh) 2020-01-16
ECSP20075234A (es) 2020-12-31
CN112703203A (zh) 2021-04-23
WO2019224713A3 (en) 2020-01-02
PH12020551948A1 (en) 2021-08-16
CA3101304A1 (en) 2019-11-28
TWI865451B (zh) 2024-12-11
AU2019274652B2 (en) 2026-03-26
CL2020003032A1 (es) 2021-04-16
EA202092849A1 (ru) 2021-03-16
NI202000087A (es) 2021-03-23
MX2020012589A (es) 2021-01-29
CO2020014515A2 (es) 2020-12-10
MA52772A (fr) 2021-04-14
IL278862A (en) 2021-01-31
PE20210634A1 (es) 2021-03-23
AU2019274652A1 (en) 2020-11-26
CN112703203B (zh) 2025-02-25
SG11202011268VA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
US20230322924A1 (en) Anti-cd3 antibodies and uses thereof
JP7506817B2 (ja) カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
TWI865451B (zh) 單特異性及多特異性抗ｔｍｅｆｆ２抗體及其用途
JP2022068193A (ja) 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
JP7049988B2 (ja) 抗ｃｄ１５４抗体及びこれを使用する方法
JP2023528350A (ja) Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
JP2024504758A (ja) Ｐｓｍａ結合タンパク質及びその使用
JP2026048645A (ja) デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
US20250136688A1 (en) Stabilized cd3 antigen binding agents and methods of use thereof
JP2025083342A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
HK40126767A (zh) 抗cd3抗体及其用途
TW202428620A (zh) Msln及cd3結合劑及其使用方法
JP2026510316A (ja) 抗ｃｌｄｎ６抗体及び使用方法
EA045935B1 (ru) Антитела к cd3 и их применение
BR112021003089A2 (pt) anticorpos biespecíficos anti-pd-l1/anti-lag3 e seus usos
HK40052977A (en) Anti-cd3 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109